Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors

• Published in: BMC cancer Vol. 23; no. 1; pp. 234 - 10
• Main Authors: Huang, Chun-Ta, Lin, Chih-An, Su, Te-Jen, Yang, Ching-Yao, Tsai, Tzu-Hsiu, Hsu, Chia-Lin, Liao, Wei-Yu, Chen, Kuan-Yu, Ho, Chao-Chi, Yu, Chong-Jen
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 13.03.2023; BioMed Central; BMC
• Subjects: Adenocarcinoma; Afatinib - therapeutic use; Biopsy; Cancer therapies; Carcinoma, Non-Small-Cell Lung - diagnosis; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Development and progression; Droplet digital polymerase chain reaction; Drug Resistance, Neoplasm - genetics; Drug therapy; EGFR mutation; Epidermal growth factor receptors; ErbB Receptors - genetics; Erlotinib Hydrochloride - therapeutic use; Gefitinib; Gefitinib - therapeutic use; Gene mutations; Genotyping; Health aspects; Humans; Inhibitor drugs; Laboratories; Lung cancer; Lung cancer, Non-small cell; Lung Neoplasms - diagnosis; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Medical research; Mutants; Mutation; Non-small cell lung carcinoma; Osimertinib; Plasma; Polymerase chain reaction; Prospective Studies; Protein Kinase Inhibitors - therapeutic use; Targeted cancer therapy; Testing; Tyrosine kinase inhibitor; Tyrosine Kinase Inhibitors; Taiwan; United States > US; EGFR mutation; Osimertinib; Tyrosine kinase inhibitor; Droplet digital polymerase chain reaction; Lung cancer

The T790M mutation is the major resistance mechanism to first- and second-generation TKIs in EGFR-mutant NSCLC. This study aimed to investigate the utility of droplet digital PCR (ddPCR) for detection of T790M in plasma circulating tumor DNA (ctDNA), and explore its impact on prognosis. This prospec...